Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Akira Kunitomi is active.

Publication


Featured researches published by Akira Kunitomi.


FEBS Open Bio | 2015

Impaired respiratory function in MELAS‐induced pluripotent stem cells with high heteroplasmy levels

Masaki Kodaira; Hideyuki Hatakeyama; Shinsuke Yuasa; Tomohisa Seki; Toru Egashira; Shugo Tohyama; Yusuke Kuroda; Atsushi Tanaka; Shinichiro Okata; Hisayuki Hashimoto; Dai Kusumoto; Akira Kunitomi; Makoto Takei; Shin Kashimura; Tomoyuki Suzuki; Gakuto Yozu; Masaya Shimojima; Chikaaki Motoda; Nozomi Hayashiji; Yuki Saito; Yu Ichi Goto; Keiichi Fukuda

Mitochondrial diseases are heterogeneous disorders, caused by mitochondrial dysfunction. Mitochondria are not regulated solely by nuclear genomic DNA but by mitochondrial DNA. It is difficult to develop effective therapies for mitochondrial disease because of the lack of mitochondrial disease models. Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke‐like episodes (MELAS) is one of the major mitochondrial diseases. The aim of this study was to generate MELAS‐specific induced pluripotent stem cells (iPSCs) and to demonstrate that MELAS‐iPSCs can be models for mitochondrial disease. We successfully established iPSCs from the primary MELAS‐fibroblasts carrying 77.7% of m.3243A>G heteroplasmy. MELAS‐iPSC lines ranged from 3.6% to 99.4% of m.3243A>G heteroplasmy levels. The enzymatic activities of mitochondrial respiratory complexes indicated that MELAS‐iPSC‐derived fibroblasts with high heteroplasmy levels showed a deficiency of complex I activity but MELAS‐iPSC‐derived fibroblasts with low heteroplasmy levels showed normal complex I activity. Our data indicate that MELAS‐iPSCs can be models for MELAS but we should carefully select MELAS‐iPSCs with appropriate heteroplasmy levels and respiratory functions for mitochondrial disease modeling.


Nature Communications | 2015

G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy

Nozomi Hayashiji; Shinsuke Yuasa; Yuko Miyagoe-Suzuki; Mie Hara; Naoki Ito; Hisayuki Hashimoto; Dai Kusumoto; Tomohisa Seki; Shugo Tohyama; Masaki Kodaira; Akira Kunitomi; Shin Kashimura; Makoto Takei; Yuki Saito; Shinichiro Okata; Toru Egashira; Jin Endo; Toshikuni Sasaoka; Shin'ichi Takeda; Keiichi Fukuda

Duchenne muscular dystrophy (DMD) is a chronic and life-threatening disease that is initially supported by muscle regeneration but eventually shows satellite cell exhaustion and muscular dysfunction. The life-long maintenance of skeletal muscle homoeostasis requires the satellite stem cell pool to be preserved. Asymmetric cell division plays a pivotal role in the maintenance of the satellite cell pool. Here we show that granulocyte colony-stimulating factor receptor (G-CSFR) is asymmetrically expressed in activated satellite cells. G-CSF positively affects the satellite cell population during multiple stages of differentiation in ex vivo cultured fibres. G-CSF could be important in developing an effective therapy for DMD based on its potential to modulate the supply of multiple stages of regenerated myocytes. This study shows that the G-CSF-G-CSFR axis is fundamentally important for long-term muscle regeneration, functional maintenance and lifespan extension in mouse models of DMD with varying severities.


PLOS ONE | 2014

Generation and characterization of functional cardiomyocytes derived from human T cell-derived induced pluripotent stem cells.

Tomohisa Seki; Shinsuke Yuasa; Dai Kusumoto; Akira Kunitomi; Yuki Saito; Shugo Tohyama; Kojiro Yae; Yoshikazu Kishino; Marina Okada; Hisayuki Hashimoto; Makoto Takei; Toru Egashira; Masaki Kodaira; Yusuke Kuroda; Atsushi Tanaka; Shinichiro Okata; Tomoyuki Suzuki; Mitsushige Murata; Jun Fujita; Keiichi Fukuda

Induced pluripotent stem cells (iPSCs) have been proposed as novel cell sources for genetic disease models and revolutionary clinical therapies. Accordingly, human iPSC-derived cardiomyocytes are potential cell sources for cardiomyocyte transplantation therapy. We previously developed a novel generation method for human peripheral T cell-derived iPSCs (TiPSCs) that uses a minimally invasive approach to obtain patient cells. However, it remained unknown whether TiPSCs with genomic rearrangements in the T cell receptor (TCR) gene could differentiate into functional cardiomyocyte in vitro. To address this issue, we investigated the morphology, gene expression pattern, and electrophysiological properties of TiPSC-derived cardiomyocytes differentiated by floating culture. RT-PCR analysis and immunohistochemistry showed that the TiPSC-derived cardiomyocytes properly express cardiomyocyte markers and ion channels, and show the typical cardiomyocyte morphology. Multiple electrode arrays with application of ion channel inhibitors also revealed normal electrophysiological responses in the TiPSC-derived cardiomyocytes in terms of beating rate and the field potential waveform. In this report, we showed that TiPSCs successfully differentiated into cardiomyocytes with morphology, gene expression patterns, and electrophysiological features typical of native cardiomyocytes. TiPSCs-derived cardiomyocytes obtained from patients by a minimally invasive technique could therefore become disease models for understanding the mechanisms of cardiac disease and cell sources for revolutionary cardiomyocyte therapies.


Stem cell reports | 2016

H1foo Has a Pivotal Role in Qualifying Induced Pluripotent Stem Cells

Akira Kunitomi; Shinsuke Yuasa; Fumihiro Sugiyama; Yuki Saito; Tomohisa Seki; Dai Kusumoto; Shin Kashimura; Makoto Takei; Shugo Tohyama; Hisayuki Hashimoto; Toru Egashira; Yoko Tanimoto; Saori Mizuno; Shoma Tanaka; Hironobu Okuno; Kazuki Yamazawa; Hideo Watanabe; Mayumi Oda; Ruri Kaneda; Yumi Matsuzaki; Toshihiro Nagai; Hideyuki Okano; Ken Ichi Yagami; Mamoru Tanaka; Keiichi Fukuda

Summary Embryonic stem cells (ESCs) are a hallmark of ideal pluripotent stem cells. Epigenetic reprogramming of induced pluripotent stem cells (iPSCs) has not been fully accomplished. iPSC generation is similar to somatic cell nuclear transfer (SCNT) in oocytes, and this procedure can be used to generate ESCs (SCNT-ESCs), which suggests the contribution of oocyte-specific constituents. Here, we show that the mammalian oocyte-specific linker histone H1foo has beneficial effects on iPSC generation. Induction of H1foo with Oct4, Sox2, and Klf4 significantly enhanced the efficiency of iPSC generation. H1foo promoted in vitro differentiation characteristics with low heterogeneity in iPSCs. H1foo enhanced the generation of germline-competent chimeric mice from iPSCs in a manner similar to that for ESCs. These findings indicate that H1foo contributes to the generation of higher-quality iPSCs.


International Journal of Cardiology | 2015

Predictive factors of lead failure in patients implanted with cardiac devices

Yoshiyasu Aizawa; Masachika Negishi; Shin Kashimura; Kazuaki Nakajima; Akira Kunitomi; Yoshinori Katsumata; Takahiko Nishiyama; Takehiro Kimura; Nobuhiro Nishiyama; Kotaro Fukumoto; Yoko Tanimoto; Shun Kohsaka; Seiji Takatsuki; Keiichi Fukuda

INTRODUCTION Lead failures (LFs) are one of the most common complications in patients implanted with cardiovascular implantable electronic devices. LFs often cause serious secondary complications such as inappropriate ICD shocks or asystole. This study aimed to identify the clinical factors associated with the occurrence of LFs. METHODS A total of 735 consecutive device implantations (mean age 67±15years, males 64%) performed at a single university hospital setting from 1997 to 2014 were included. The implanted devices consisted of 421 pacemakers, 250 implantable cardioverter defibrillators (ICD), 9 cardiac resynchronization therapy pacemakers (CRT-P), and 55 CRT defibrillators (CRT-D). The primary endpoint was the development of an LF. RESULTS During a mean duration of 5.8±4.3years, 38 LFs developed in 31 patients (mean age 56±14years). LFs included 32 ICD (7 Sprint Fidelis, 2 Riata), and 6 pacing leads. Nine patients received inappropriate ICD shocks and 1 had syncope due to an LF. All patients underwent lead reinsertions with device replacements. Eight patients required opposite site implantations due to venous occlusions. The predictive factors of LFs were the age, male sex, taller body length, ICD vs. pacemaker, lesser lead number, extra-thoracic puncture of the axillary vein vs. a cut-down of the cephalic vein, use of recalled leads and patients with idiopathic ventricular fibrillation (IVF) and Brugada syndrome (BrS). CONCLUSION LFs occurred mainly with ICD leads. A lesser age, the puncture method, lead model, and diagnosis of IVF/BrS were associated with the development of LFs.


Stem Cells International | 2013

Distinct iPS Cells Show Different Cardiac Differentiation Efficiency

Yohei Ohno; Shinsuke Yuasa; Toru Egashira; Tomohisa Seki; Hisayuki Hashimoto; Shugo Tohyama; Yuki Saito; Akira Kunitomi; Kenichiro Shimoji; Takeshi Onizuka; Toshimi Kageyama; Kojiro Yae; Tomofumi Tanaka; Ruri Kaneda; Fumiyuki Hattori; Mitsushige Murata; Kensuke Kimura; Keiichi Fukuda

Patient-specific induced pluripotent stem (iPS) cells can be generated by introducing transcription factors that are highly expressed in embryonic stem (ES) cells into somatic cells. This opens up new possibilities for cell transplantation-based regenerative medicine by overcoming the ethical issues and immunological problems associated with ES cells. Despite the development of various methods for the generation of iPS cells that have resulted in increased efficiency, safety, and general versatility, it remains unknown which types of iPS cells are suitable for clinical use. Therefore, the aims of the present study were to assess (1) the differentiation potential, time course, and efficiency of different types of iPS cell lines to differentiate into cardiomyocytes in vitro and (2) the properties of the iPS cell-derived cardiomyocytes. We found that high-quality iPS cells exhibited better cardiomyocyte differentiation in terms of the time course and efficiency of differentiation than low-quality iPS cells, which hardly ever differentiated into cardiomyocytes. Because of the different properties of the various iPS cell lines such as cardiac differentiation efficiency and potential safety hazards, newly established iPS cell lines must be characterized prior to their use in cardiac regenerative medicine.


PLOS ONE | 2014

Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions.

Yoshikazu Kishino; Tomohisa Seki; Jun Fujita; Shinsuke Yuasa; Shugo Tohyama; Akira Kunitomi; Ryota Tabei; Kazuaki Nakajima; Marina Okada; Akinori Hirano; Hideaki Kanazawa; Keiichi Fukuda

Recently, induced pluripotent stem cells (iPSCs) were established as promising cell sources for revolutionary regenerative therapies. The initial culture system used for iPSC generation needed fetal calf serum in the culture medium and mouse embryonic fibroblast as a feeder layer, both of which could possibly transfer unknown exogenous antigens and pathogens into the iPSC population. Therefore, the development of culture systems designed to minimize such potential risks has become increasingly vital for future applications of iPSCs for clinical use. On another front, although donor cell types for generating iPSCs are wide-ranging, T cells have attracted attention as unique cell sources for iPSCs generation because T cell-derived iPSCs (TiPSCs) have a unique monoclonal T cell receptor genomic rearrangement that enables their differentiation into antigen-specific T cells, which can be applied to novel immunotherapies. In the present study, we generated transgene-free human TiPSCs using a combination of activated human T cells and Sendai virus under defined culture conditions. These TiPSCs expressed pluripotent markers by quantitative PCR and immunostaining, had a normal karyotype, and were capable of differentiating into cells from all three germ layers. This method of TiPSCs generation is more suitable for the therapeutic application of iPSC technology because it lowers the risks associated with the presence of undefined, animal-derived feeder cells and serum. Therefore this work will lead to establishment of safer iPSCs and extended clinical application.


Scientific Reports | 2017

Emerin plays a crucial role in nuclear invagination and in the nuclear calcium transient

Masaya Shimojima; Shinsuke Yuasa; Chikaaki Motoda; Gakuto Yozu; Toshihiro Nagai; Shogo Ito; Mark Lachmann; Shin Kashimura; Makoto Takei; Dai Kusumoto; Akira Kunitomi; Nozomi Hayashiji; Tomohisa Seki; Shugo Tohyama; Hisayuki Hashimoto; Masaki Kodaira; Toru Egashira; Kenshi Hayashi; Chiaki Nakanishi; Kenji Sakata; Masakazu Yamagishi; Keiichi Fukuda

Alteration of the nuclear Ca2+ transient is an early event in cardiac remodeling. Regulation of the nuclear Ca2+ transient is partly independent of the cytosolic Ca2+ transient in cardiomyocytes. One nuclear membrane protein, emerin, is encoded by EMD, and an EMD mutation causes Emery-Dreifuss muscular dystrophy (EDMD). It remains unclear whether emerin is involved in nuclear Ca2+ homeostasis. The aim of this study is to elucidate the role of emerin in rat cardiomyocytes by means of hypertrophic stimuli and in EDMD induced pluripotent stem (iPS) cell-derived cardiomyocytes in terms of nuclear structure and the Ca2+ transient. The cardiac hypertrophic stimuli increased the nuclear area, decreased nuclear invagination, and increased the half-decay time of the nuclear Ca2+ transient in cardiomyocytes. Emd knockdown cardiomyocytes showed similar properties after hypertrophic stimuli. The EDMD-iPS cell-derived cardiomyocytes showed increased nuclear area, decreased nuclear invagination, and increased half-decay time of the nuclear Ca2+ transient. An autopsied heart from a patient with EDMD also showed increased nuclear area and decreased nuclear invagination. These data suggest that Emerin plays a crucial role in nuclear structure and in the nuclear Ca2+ transient. Thus, emerin and the nuclear Ca2+ transient are possible therapeutic targets in heart failure and EDMD.


International Journal of Cardiology | 2018

Prevalence and clinical characteristics of obstructive- and central-dominant sleep apnea in candidates of catheter ablation for atrial fibrillation in Japan

Takashi Kohno; Takehiro Kimura; Koichi Fukunaga; Wakako Yamasawa; Taishi Fujisawa; Ryoma Fukuoka; Kazuaki Nakajima; Shin Kashimura; Akira Kunitomi; Yoshinori Katsumata; Takahiko Nishiyama; Nobuhiro Nishiyama; Yoshiyasu Aizawa; Keiichi Fukuda; Seiji Takatsuki

INTRODUCTION We aimed to study the prevalence and types of sleep apnea (SA) as well as their clinical characteristics in atrial fibrillation (AF) ablation candidates in Japan. METHODS Before catheter ablation, 197 consecutive AF patients (age: 60 ± 9 years, body mass index; 25.0 ± 3.0) were evaluated with portable polygraphy. We compared the clinical characteristics, according to the severity of SA as well as its types, as defined by the presence of obstruction and the mixed vs. central apnea indices. RESULTS The mean apnea-hypopnea index (AHI) was 17.7 ± 11.9, with 135 AF patients having an AHI ≥10 (68.5%). Patients with an AHI ≥10 had a significantly higher body mass index, plasma brain natriuretic peptide (BNP) level, prevalence of hypertension, and larger left atrial size. Among patients with an AHI ≥10, the incidence of obstructive-dominant SA was 60.9% and that of central-dominant SA was 7.6%. The prevalence of hypertension was significantly higher in obstructive-dominant SA patients (obstructive vs. central: 48.3% vs. 20.0%, P = 0.038). The obstructive apnea index correlated with plasma BNP level and age, but the central and mixed apnea indices did not. CONCLUSIONS The prevalence of SA was common in AF ablation candidates, even without an obesity epidemic, and the SA type was predominantly obstructive. Portable polygraphy was useful for detecting undiagnosed SA patients in AF ablation candidates.


Journal of Cardiology | 2017

A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan

Takehiro Kimura; Ataru Igarashi; Shunya Ikeda; Kazuaki Nakajima; Shin Kashimura; Akira Kunitomi; Yoshinori Katsumata; Takahiko Nishiyama; Nobuhiro Nishiyama; Kotaro Fukumoto; Yoko Tanimoto; Yoshiyasu Aizawa; Keiichi Fukuda; Seiji Takatsuki

BACKGROUND We aimed to clarify the cost-effectiveness of an expensive combination therapy for atrial fibrillation (AF) using both catheter ablation and dabigatran compared with warfarin at each CHADS2 score for patients in Japan. METHODS A Markov model was constructed to analyze costs and quality-adjusted life years associated with AF therapeutic options with a time horizon of 10 years. The target population was 60-year-old patients with paroxysmal AF. The indication for anticoagulation was determined according to the Japanese guideline. Anticoagulation-related data were derived from the RE-LY study and the AF recurrence rate was set at 2.7% per month during the first 12 months and at 0.40% per month afterwards. Stroke risk was determined according to AF recurrence, anticoagulation, and CHADS2 score. The risks for stroke recurrence and stroke death were also considered. Costs were calculated from the healthcare payers perspective, and only direct medical costs were included. RESULTS Warfarin was the most preferred option for patients with a CHADS2 score of 0 from a health economics aspect. Ablation under warfarin was preferred for a CHADS2 score of 1-3, while ablation under dabigatran was preferred for a CHADS2 score ≥4. The quality of life score for AF had the largest impact on the incremental cost-effectiveness ratios in the analysis between the anticoagulation arm and the anticoagulation+ablation arm for a CHADS2 score of 2. Within the range of the Japanese willingness-to-pay threshold (¥5,000,000), the ablation+warfarin arm became the best option with its probability of 81.7% for a CHADS2 score of 2; the dabigatran+ablation arm was the most preferred option with its probability of 56.1% for a CHADS2 score of 4. CONCLUSIONS Ablation under dabigatran therapy is an expensive therapeutic option, but it might benefit patients with a low quality of life and a high CHADS2 score.

Collaboration


Dive into the Akira Kunitomi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge